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Abstract The common view of amyloids and prion proteins is that they are associated with
many currently incurable diseases and present a great danger to an organism. This danger
comes from the fact that not only prion proteins, but also the infectious form(s) of amyloids,
as it has been shown recently, are able to transmit the disease. On the other hand, organisms
take advantage of the strength and durability of specific forms of amyloids. Such forms do
not spread any disease. Also, in nanotechnology there is a constantly growing need to
employ amyloid fibrils in many industrial applications. With increasing knowledge about
amyloids and prion proteins we are aware that the amyloidal state is inherent to any protein,
making the problem of amyloid formation a central one in aging-related diseases. However,
the “good” amyloids can be beneficial and even necessary for our health. Furthermore,
because of their mechanical properties, the amyloids are of great interest to engineers.
Keywords Amyloids . Prions . Fibrils . Amylome . Amyloidogenic segments . Aging
diseases
The World of Amyloids—Amylome
Many proteins can convert into amyloid fibrils either to comply with the physiological needs
or as part of a pathological scenario. To fight against pathological amyloid states and to stop
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growth of particular amyloids, the prospective inhibitors of amyloid fibril formation may be
helpful. Unfortunately, the structure-based drug design is hampered because amyloid pro-
teins do not have defined structures. Nonetheless, in a recent paper [1], the Eisenberg and
Baker groups described a structure-based design of such inhibitors. They demonstrated [1]
that a structure of a short segment directly engaged in fibril formation can be sufficient for
the design of fibril formation inhibitors and that the computational methods may be
successful in designing novel peptide–peptide interfaces. The inhibitory peptides were
designed employing modeled structures of the so-called “steric zippers” which are dual β-
sheets. One of the inhibitory peptides, consisting exclusively of D-amino acids, inhibited the
formation of the tau protein tangles associated with Alzheimer’s disease [2]. Its target was a
hexapeptide VQIVYK corresponding to tau protein residues 306–311. This fragment was
shown to be important for fibril formation by the full-length tau protein [3, 4], and fibrils
formed by this fragment are similar to full-length tau fibrils. The researchers also designed a
non-natural L-amino acid inhibitor of the amyloid fibril enhancing transmission of HIV. Its
target was also a steric zipper structure of the GGVLVN peptide from a fragment of prostatic
acid phosphatase [5]. The authors designed the specific and tight interface between the
inhibiting peptide and the end of the steric zipper by maximizing the number of hydrogen
bonds and hydrophobic interactions.
Eisenberg also introduced the concept of amylome [6] defined as a large set of proteins
capable of forming amyloid-like fibrils. It was suggested in this paper that the amyloid state
is accessible to many more proteins that was originally thought—not only to those whose
entire sequence is engaged in amyloid formation. In the classical view, in each disease of
amyloid origin, one or two fibril-forming proteins were characterized, namely β-amyloid
and tau proteins in Alzheimer’s disease, α-synuclein in Parkinson’s disease, huntingtin
polyglutamine stretch in Huntington’s disease, prion protein in Creutzfeldt-Jakob disease
and amylin in type II diabetes [7]. Aggregates of these proteins are toxic, highly stable, and
are producing polymer-like amyloids by recruiting normal, soluble proteins [8].
Eisenberg and coworkers [6] investigated the factors that enable a protein to acquire an
amyloidal form. It turned out that the major factor responsible for amyloid formation is the
presence of a segment in the protein that can form a tightly complementary interface with
other mostly identical segments. Such interface between the segments was named “steric
zipper.” It is usually created by self-complementary β-sheets that form the amyloid fibril.
Another suggested factor is a sufficient conformational freedom of the self-complementary
segment allowing for interaction with other identical segments. Eisenberg’s group examined
more than 12,000 proteins whose folded, three-dimensional (3D) structures are already
known. The predictions of an amyloid state were done by the modified 3D-Profile method
[9] based on the crystal structure of the NNQQNY motif, known to form a steric zipper.
They computationally examined proteins of three organisms: Escherichia coli, Saccharo-
myces cerevisiae, and Homo sapiens. The method identified protein segments with high
tendency to form amyloid fibrils and demonstrated that a specific residue order is required
for fiber formation. These segments were typically about six amino acids long and could be
exposed for instance during thermal motion of the protein. It was found that 95% of the
predicted amyloid-prone segments are buried within the protein, and those that are exposed
are too twisted and inflexible to form a “steric zipper” with partner segments. Using bovine
pancreatic ribonuclease A (RNase A) as a model system, they experimentally validated the
accuracy of predictions and investigated the effect of sequence and residue composition. For
instance, the FERQHM sequence was one of several segments predicted and experimentally
confirmed not to form fibrils. However, when the residues of this segment were rearranged
to QEMRHF, the energy of the rearranged segment fell below the formerly estimated
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threshold of −23 kcal/mol; QEMRHF was thus predicted to form fibrils, which was
subsequently confirmed by EM images. On the contrary, the fibril-forming segments
QANKHI and STMSIT were rearranged to IHKAQN and ISMTTS, respectively. The
rearranged sequences were predicted not to form fibrils, and it was also confirmed by
experimental methods. Such shuffling experiments suggest that the tendency to form
amyloid-like fibrils is strongly sequence-dependent and relatively insensitive to amino acid
composition.
In earlier research it has also been shown [10, 11] that many globular proteins can be
converted to the amyloid state by a variety of denaturing processes, suggesting that conver-
sion may generally be applicable to all proteins. The self-association of peptides and proteins
into well-ordered supramolecular structures is of central importance in normal physiological
processes such as the assembly of collagen fibrils [12, 13], actin filaments [14] but also in
pathophysiological cases [15]. Integration of old and new techniques and development of
novel methods of nanoscience can provide powerful opportunities to increase our under-
standing of processes underlying amyloid-related disorders [16]. Until recently, it was
commonly believed that amyloid formation is a feature of only a tiny fraction of proteins.
Not all proteins, however, form amyloids because in most cases these potentially harmful
segments are hidden deep inside the protein structure and are kept under control. Such
behavior can be of evolutionary origin suggesting that evolution treats amyloids as a
fundamental threat. The presence of different kinds of amyloids have been confirmed in
some of the most common age-related diseases, so one can suppose that the accumulation of
amyloid is unavoidable during aging. Sometimes, the presence of amyloid deposits does not
give rise to neurodegenerative symptoms, indicating that amyloid fibrils do not cause the
onset of disease. Therefore, one of the hypotheses suggested that the oligomeric intermedi-
ates are the toxic species while the fibrils are detoxification products [17]. Fibrils are not the
only shape taken by amyloids especially during the nucleation process. For instance,
spheroidal oligomeric species have been demonstrated for α-synuclein—they are thought
to be responsible for cytotoxicity towards the neuronal cells observed in Parkinson’s disease
[18, 19].
On the basis of current research, it was proposed by Eisenberg [6] that the amyloid
state is more like a default state of a protein especially in the absence of specific
protective mechanisms such as chaperoning. Proteins that are not correctly folded and
less protected (by chaperoning and/or disposal mechanisms) are predisposed to become
amyloids. The amyloid-associated diseases that are known so far probably involve only
the most vulnerable human proteins. Many research groups try to find ways to
supplement or boost the protective mechanisms, in the hope of treating or preventing
the original cause of amyloid-linked diseases. Even a subtle pharmacological interfer-
ence in the process of amyloidogenesis might have a major effect on the disease and
even on ageing in general. On the other hand, one can enhance the natural protective
mechanisms that stabilize a protein. A review of potential strategies for tackling protein
aggregation and the toxicity associated with it has been published by Bartolini and
Andrisano [20]. However, the complexity of the aggregation processes and other related
events account for the fact that no effective treatments for these disorders are currently
available. Studies of the structures of amyloids and mechanisms of amyloid formation
should unveil new molecular targets for potential anti-neurodegenerative drugs. Al-
though the three characteristic stages of nucleation-dependent fibrillation—seed forma-
tion, accelerated fibrillar growth, and the stationary phase—have been examined
separately, additional studies are required to unambiguously uncover the mechanism
of amyloidogenesis.
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Molecular Structures of Amyloids
Amyloid fibrils represent an energetically stable state of many proteins and peptides.
Basically, amyloid fibers are a bundle of highly ordered filaments composed of ladders of
β-strands that are placed perpendicular to the fiber axis and are arranged in hydrogen-
bonded β-sheets [21]. Amyloid fibers have a diameter of about 7–10 nm and can be up to
several micrometers long. In cross sections, amyloid assemblies appear as hollow cylinders
or ribbons. The measurements of amyloid fibers revealed that their strength is comparable to
that of steel while their mechanical stiffness matches that of silk [22]. In general, amyloid
structures attain their stability through non-covalent bonds, mainly hydrogen bonds stabi-
lizing the β-sheets, but also through hydrophobic and π–π stacking interactions of the side
chains. The frequent occurrence of aromatic residues in short amyloid-related peptides
suggests that π stacking may play a role in speeding-up the self-assembly process by
providing geometrical constraints that promote directionality and orientation of the growing
fibril. The importance of hydrogen bonds is especially seen in glutamine- and asparagine-
rich proteins which form amyloids. Extended sequences of repeated glutamine (or aspara-
gine) units are related to several amyloidoses such as Huntington’s disease and spinocer-
ebellar ataxia, and also to the aggregation of yeast proteins into prions.
The three-dimensional structure of the fibrils comprising Aβ42 (Protein Data Bank code
2BEG) was obtained using quenched hydrogen/deuterium exchange NMR in solution, while
the β-sheet arrangement was taken from previous solid-state NMR studies of this structure.
Residues 18–42 form a β–strand–turn–β–strand motif while residues 1–17 are disordered
and could not be detected. The parallel β-sheets are formed by residues 18–26 (β1 strand)
and 31–42 (β2 strand). The repeating structure of a protofilament requires two monomers
because of the salt bridge D23-K28 formed between adjacent monomers. This interaction
pattern leads to the formation of partially unpaired β-strands at the ends of the Aβ42 fibrils
(Fig. 1). Such unpaired ends explain the specific shape of these fibrils and could be a target
for inhibitors of fibril growth [23]. The salt bridge and also the hydrophobic interactions of
the side chains keep the structure rigid and compact despite the repulsion between the
charged residues E22, D23, and K28 from the adjacent β-strands.
Amyloid fibrils can be formed by different proteins and usually contain a common cross-
β spine. Glutamine repeats were first suggested to act as “polar zippers” joining monomeric
units together and propagating the amyloid fibrils. The structure of the fibril-forming
segment, GNNQQNY, of the yeast prion protein Sup35 has been recently revealed by
crystallography [24]. It is formed by a pair of β-sheets, with the facing side chains of the
Fig. 1 The structure of fragment
of β-amyloid (Aβ42) obtained by
NMR methods (PDB code
2BEG). The salt bridge K28-D23
is linking adjacent β-sheets,
therefore, the residues K28 and
D23 from terminal strands are
unpaired (marked). A salt bridge
K28-D23 was marked with a
dotted ellipse. Hydrogen bonds
shown as dashed cylinders
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two sheets locked together in an interdigitated way forming a so-called “dry steric zipper”
(Fig. 2a). Eisenberg and coworkers [24] reported dozens of other segments from fibril-
forming proteins that are able to form amyloid-like fibrils on their own. The segments from
the β-amyloid and tau proteins, the PrP prion protein, insulin, islet amyloid polypeptide
(IAPP), lysozyme, myoglobin, α-synuclein, and β-2-microglobulin were analyzed. The
obtained structures are characterized by structural features that are shared, at the molecular
level, by all the proteins studied but some variations in the atomic architecture of the
amyloid-like fibrils can provide some clues on their origin and the mode of growth. In the
GNNQQNY amyloid, the peptide strands are parallel, and the Asn and Gln residues form
regular rows connected by hydrogen bonds in addition to the hydrogen bonds in the β-sheet.
The hydrophilic character of these residues and their length make the steric zipper interface
highly interdigitated. In the other amyloid formed from the AILSST peptide (Fig. 2b), the
strands are antiparallel, and the steric zipper interface is formed mostly by hydrophobic
residues Ile and Leu. The hydrogen bonds between side chains of serine residues are bridged
by water molecules.
According to [24] there are eight types of the steric zipper interfaces classified according
not only to the orientations of their strands (parallel or antiparallel) but also faces (face-to-
face or face-to-back arrangement) and the up or down orientations of the edges of the
strands. So identical peptides can form different polymorphic structures characterized by
distinctive phenotypes. New polymorphic crystal structures of segments of the prion and
other amyloid proteins [25] proved to be useful for elucidating the structural mechanisms of
different modes of fibrillation. Additionally, β-sheets formed by the same segment of a
protein can reveal alternative packing arrangements (polymorphs). Such polymorphism can
be responsible for enduring conformations capable of “encoding” prion strains. Such transfer
of protein-encoded information into prion strains involves sequence specificity and recog-
nition by means of noncovalent bonds.
Mechanisms of Amyloid Formation
Amyloid fibril formation is considered to be a signature of neurodegenerative processes. The
exact processes leading to cellular degeneration remain unknown although several amyloid-
involving mechanisms have been proposed [26]: (1) amyloids occupy the extracellular space
and destroy the structure of cells and tissues, (2) amyloid fibrils destabilize cell membranes,
(3) heavy metals incorporate into amyloids and generate reactive oxygen compounds which
affect cellular functions, (4) some proteins essential for cell survival are trapped in protein
aggregates. In a recent review, Zerovnik et al. [27] classified the mechanisms by which
Fig. 2 The crystal structures of
amyloids a GNNQQNY (PDB
code 2OMM), adjacent β-strands
are parallel, and b AILSST (PDB
code 3FOD), adjacent β-strands,
are antiparallel. Hydrogen bonds
shown as dashed cylinders
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proteins undergo ordered aggregation into amyloid fibrils: (1) templating and nucleation; (2)
linear, colloid-like assembly of spherical oligomers, and (3) domain swapping. The local
environment and inter- and/or intra-molecular interactions may have a significant influence
on the conformation of certain amino acid residues. Therefore, even small variations in pH,
temperature, and ionic strength could induce changes in the conformational propensities of
these residues (leading to a different secondary structure) including their ability to aggregate.
Some proteins forming amyloids, for instance α-synuclein which contributes to the forma-
tion of intracellular Lewy bodies in Parkison’s disease [28], can exist without a defined
structure. It was postulated that exogenous α-synuclein fibrils induce the formation of Lewy
body-like intracellular inclusions [29]. Other proteins with an unordered structure are the IAPP
in type II diabetes [30] and β-amyloid in Alzheimer’s disease [31]. Such an unfolded structure
allows the protein to be rather easily self-assembled into fibrils. On the other hand, some
amyloidogenic proteins preserve their 3D structure until the actual fibrillation [11]. This group
of proteins includes β-2 microglobulin identified in dialysis-related amyloidosis [32], hunting-
tin in Huntington’s disease [33], immunoglobulin VL domain in light-chain amyloidosis [34],
lysozyme in hereditary systemic amyloidosis [35], prion protein in Creutzfeldt-Jakob disease
[36], and transthyretin in senile systemic amyloidosis [37]. However, regardless of the initial
structure, the amyloid fibrils obtained from different amyloidogenic proteins and peptides are
very similar and adopt a cross β-sheet conformation [10] even though these proteins and
peptides share rather little amino acid sequence similarity. It was known that even all α (protein
composed of α-helices only) or mixed α/β protein types can form β-sheet fibrils. Therefore, it
was tempting to suggest that when elucidated for a given protein in a particular disease, the
molecular mechanism of amyloidogenesis will apply to other proteins and amyloid-related
diseases. However, it became gradually recognized that amyloid fibrils exist in multiple fibrillar
forms and exhibit so-called fibrillar polymorphisms. Even a single amyloidogenic protein can
create multiple forms of amyloid fibrils depending on the conditions in which fibrillation
occurred. This may indicate that amyloidogenesis can proceed via multiple mechanisms.
Various types of possible amyloids structures are shown on Fig. 3.
The conversion and aggregation of proteins from their soluble states into well-organized
fibrils is associated with a wide range of conditions, usually pathological, including neurode-
generative diseases and amyloidoses. Although a conformational change of the protein native
state is generally necessary to initiate aggregation, it was shown that a transition across the large
Fig. 3 Different forms of amy-
loids: a squared plates, b nano-
spheres, c hydrogels, d tubular
structures—single-walled and
multi-walled tubes, e fibrils
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unfolding energy barrier is not essential and that the aggregation may be initiated from locally
unfolded states that become accessible, for example, via thermal fluctuations occurring under
physiological conditions [11]. Conformational states thermodynamically distinct from the
native state, but structurally similar to it, can be easily accessed from the native state through
thermal fluctuations. These states are separated from the native state by a relatively low energy
barrier. They are therefore only transiently populated under physiological conditions, yet they
can be sampled more frequently than the entirely unfolded state (global unfolding) or a partially
folded state. The existence of such conformational states can be deducted from the observation
that, under physiological conditions, the amide hydrogen atoms buried in the interior of a native
protein can exchange with the solvent hydrogen atoms more rapidly than it could be expected
from the rate of protein unfolding. The possibility of sampling of such partially unfolded states
is also confirmed by long molecular dynamics simulations.
Amyloid self-polymerization is also the basis of the “protein-only” hypothesis for the
mechanism of prion infectivity. The infectious prion conformation replicates itself in a host
by pairing with the host protein and forcing it into the infectious, fibrillar conformation. It
was found that amyloids, including β-amyloid, can also be infectious like the PrPSc prion
protein. Data showed that β-amyloid, which is associated with Alzheimer’s disease, behaved
like an infectious agent when injected into the brain of a mouse. The same mechanism was
suggested in the case of other diseases in which amyloid forms of proteins were detected
[38]. A self-complementary “steric zipper” structure identified in protein fibrils allows them
to tangle very tightly with an identical segment exposed on another protein. Several of these
segments are needed to seed, or nucleate, an amyloid. Segments attach to one another and
form fibrils. As they grow, fibrils are fringed by the remnants of the host protein segments
(Fig. 4). Eventually, this developing fibril breaks to form two smaller fibrils, each of which
starts to grow at both ends again. The nucleation events are rare but once the fibril is formed
its spreading is fast. Ohhashi et al. [39], based on mutational and biophysical analyses,
proposed that before fiber formation, the prion domain (Sup35NM, consisting of residues 1-
254) of yeast prion Sup35 forms oligomers in a temperature-dependent reversible manner.
Experiments revealed that “non-native” aromatic interactions outside the amyloid core drive
oligomer formation by bringing together different monomers, which leads to the formation
of new amyloid cores. In this way, the transient non-native interactions in the initial nucleus
are responsible for the diversity of amyloid conformations.
Kinetics of the Growth of Amyloid Fibrils
Using quantitative measurements of protein aggregation rates, Buell et al. [40] developed a
kinetic model of a conversion of a protein from a soluble to a fibrillar form which shows that
Fig. 4 A scheme displaying the
process of amyloid formation result-
ing from instability of part of the
protein structure (light gray helix).
The rest of the proteins not partici-
pating in amyloidal β-sheet devel-
opment are shown as ellipses. All
structures of proteins were created in
Yasara (YASARA Biosciences)
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there is a single free energy aggregation barrier controlling the addition of protein molecules
into amyloid fibrils. Other characteristics of the aggregation process are natural consequen-
ces of finite diffusion times. These findings suggest that this process does not follow a
simple chemical mechanism, but rather operates in a way analogous to the multitrajectory
(landscape) models of protein folding defined by stochastic dynamics on the surface of the
potential energy of the system. Another kinetic study [41] was based on quantitative quartz
crystal microbalance measurements of the kinetics of the growth of amyloid fibrils in
crowded environments. Such environments strongly modify the association of components,
through attractive entropic interactions such as the depletion pressure that results from the
entropically favorable overlap of the regions surrounding two aggregating particles. The
complex effects of macromolecular crowding on the growth of amyloid fibrils can be
described on the basis of established physical principles using a combination of osmotic
effects and entropic interactions. Within this framework, it was possible to predict the
aggregation susceptibility of many proteins with different structural properties. Campioni
et al. [42] described two types of oligomers formed by the HypF-N protein (91-residue N-
terminal domain of E. coli HypF) that are morphologically similar, as detected with atomic
force microscopy and thioflavin T assays, though one is benign when added to cell cultures,
whereas the other is toxic. They found that a lower degree of hydrophobic packing is
correlated with a higher ability to penetrate the cell membrane and to cause an influx of
calcium ions. It suggests that structural flexibility and hydrophobic exposure are primary
determinants of the ability of oligomeric assemblies to cause cellular dysfunction and its
consequences such as neurodegeneration. A broad review on aggregation kinetics and
mechanisms of fibril formation was prepared by Morris et al. [43]. By employing an
extensive mathematical framework, the authors revealed different aspects of nucleation,
growth, and disintegration of various amyloid intermediates.
Specific Mechanisms of Fibrillation
To explain the process of α-synuclein amyloidogenesis, a specific mechanism named
double-concerted fibrillation, corresponding to the prevailing nucleation-dependent fibrilla-
tion model, was introduced [44]. According to the double-concerted fibrillation, the amyloid
fibril formation is achieved via two consecutive, concerted associations of monomers and
the subsequently formed oligomeric granules. These newly formed oligomeric species act as
units for fibril formation and subsequent growth in the absence of a template [26]. Template-
dependent fibrillation requires a pre-existing fibril to which the incoming protein monomers
or granules can attach if, due to a conformational change, they match the structure of the
template. The fibril is extending, and the subsequent assembling step requires the exposure
of the interactive domains of the protein to facilitate further molecular self-assembly.
Template-dependent fibrillation is the most appropriate mechanism to study the infectivity
of prion proteins. Prion protein (PrPC) is anchored to the cellular surface via the glycosyl-
phosphatidylinositol moiety. Its conformational change into another structural entity (PrPSc)
is associated with the occurrence of transmissible spongiform encephalopathies (a group of
prion diseases). Exogenous PrPSc directs the conversion of PrPC into PrPSc conformation by
acting as a template. In a template-independent fibrillation, the amyloidogenic conforma-
tions of building units are induced (by physical or chemical influences) before the main
molecular assembly occurs. Polymorphism of amyloids, reflected by the existence of various
types of amyloid fibrils, especially in the presence of specific ligands, is achieved via
multiple pathways. The natively or partially unfolded amyloidogenic proteins are at a
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high-energy state, but increased conformational entropy could allow the self-interactive
conformers to be stabilized. Initial stable seed formation is by no means privileged since
the production of an oligomeric nucleus is an entropically expensive process which needs to
be overcome by an enthalpic advantage [26].
Another mechanism, the 3D domain swapping, has been suggested to explain the
development of protein oligomer assembly of cystatins and stefins [27]. These small
globular proteins (11–13 kDa) are part of a large family of cysteine proteinase inhibitors
which are also linked to amyloid diseases. The process of domain swapping is rate limiting
for the initiation of amyloid fibril formation because of a high energetic barrier in this
process. Nevertheless, it was suggested that, in principle, any protein is capable of oligo-
merization by 3D domain swapping [45]. Guo and Eisenberg [46] proposed the term “run-
away domain-swapping” for a process of continuous domain swapping. Wahlbom et al. [47]
used the term “propagated domain-swapping” to describe a similar process of continuous
domain swapping in the formation of cystatin C prefibrillar oligomers and fibrils.
Apart from the oligomeric species formed on the route to mature fibrils the off-pathway
oligomers are also formed. They are the dead ends of an alternative folding pathway because
they are incapable of converting directly to fibrils and substantially slow fibril formation.
The OFF model for amyloid formation was first described by Pallitto and Murphy [48]. In
this model, denatured monomers are refolded into either stable monomers or dimers or less
stable dimeric intermediates which can form non-fibrillar oligomeric forms. These initial
steps are followed by a cooperative assembly of the fibril-prone dimeric intermediates into a
nucleus from which the protofibrils originate.
Conformationally Distinct Amyloid States
Since it was known that the amino acid position specifically contributes to protein oligo-
merization, Maji et al. [49] performed amino acid substitution to determine the distribution
frequency of the Aβ oligomer. The substitutions were done at positions 1, 10, 20, 30, and 40
(for Aβ40) or 42 (for Aβ42). The effects of these mutations were probed using circular
dichroism spectroscopy, thioflavin T binding, electron microscopy, and other techniques. All
peptides displayed a transition from a random coil to α/β and to all-β structure, but
substitution-dependent changes in the kinetics of assembly and the complexity of con-
formers were observed. The ability of a single substitution (Tyr in position 1) to alter the
Aβ assembly kinetics and the oligomer frequency distribution suggests that the N-terminus
is also involved in the oligomerization process and that, most probably, there is a compe-
tition between the N- and C-termini to form a stable complex with the central hydrophobic
cluster. Additionally, recent electron microscopy and AFM data for Aβ40 suggest that
dimerization and subsequent monomer attachment are processes in which significant con-
formational changes occur in the monomer. It was also found that dimers were threefold
more toxic than monomers, and tetramers were about 13-fold more toxic [50].
Using mass spectrometry and ion mobility spectrometry Bowers and coworkers [51]
investigated a mixture of Aβ40 and Aβ42. A heterooligomer was formed composed of equal
parts of both forms of Aβ. These mixed species comprise an oligomer distribution extending
to tetramers, similar to the structures created by Aβ40, whereas Aβ42 alone produced longer
oligomers (dodecamers) indicating that Aβ40 inhibits oligomerization of Aβ42. In solution,
Aβ40 and Aβ42 adopted similar random coil structures; however, Aβ42 was significantly
more neurotoxic and formed amyloid fibrils much more rapidly than the shorter form of Aβ.
Although amyloid formation is triggered by a transient nucleus, the mechanism by which the
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initial nucleus is formed and allows the protein to acquire a specific amyloid confor-
mation is still unclear. The observation that Aβ40 and Aβ42 self-assemble via different
pathways put forward the Aβ42 dodecamers as candidate primary toxic species in
Alzheimer’s disease [52].
If mutations in sequence or changes in environmental conditions elicit partial unfolding
of the native state of a protein, the protein will tend to aggregate, sometimes into fibrillar
structures. The metastable, partially unfolded states that precede the aggregated states of
proteins are of special interest because of their specific features and especially because of
increased toxicity. It was found that protein aggregation is favored by conditions that
promote stable intermolecular interactions, particularly the hydrogen bond formation. Cal-
amai et al. [53] showed that human muscle acylphosphatase is able to form both fibrillar and
non-fibrillar aggregates with a high β-sheet content from partially unfolded states with very
different structural features due to the use of different destabilization factors: urea or
increased temperature followed by incubation in the presence of different concentrations
of 2,2,2-trifluoroethanol (solvent that has been found to promote aggregation of other
polypeptides, including the natively unfolded Aβ peptide). The same amino acid sequence
can give rise to several conformationally distinct amyloid states. To address this puzzle,
Ostapchenko et al. [54] studied two amyloid states of the prion protein (referred to as R- and
S-fibrils). The obtained results suggested that the energy landscape for protein folding and
assembly contains several close to global free-energy minima: one of which is occupied by
the native state and the remaining ones by the amyloid states. The transmissible form of
prion disease can be induced in wild-type animals by inoculation with R-fibrils while S-
fibrils failed to induce the prion disease. Recently, an apparent generation of toxic prions
(PrPSc) in normal brain tissue in the presence of metal (steel wires) has been discovered. The
metal catalyzed de novo formation of PrPSc from a normal cellular prion protein [55].
Alternatively, metal surfaces might concentrate the already existing PrPSc to the extent that
it became quantifiable by the cell assay.
Molecular Simulations of Amyloids
The long time scale in which the aggregation takes place is prohibitive for molecular
dynamics (MD) simulations. However, some structural and dynamic features of amyloids
were investigated using coarse grain protein models and specific MD or Monte Carlo
procedures. Urbanc et al. [56] elucidated the structural characteristics of oligomers of
Aβ40 and Aβ42 and of their mutants. They simulated oligomer formation using discrete
MD with a four-bead protein model (the backbone is represented by three beads
corresponding to the amide, alpha-carbon, and the carbonyl groups; the side chain, with
the exception of glycin, is represented by only one bead). For the peptides under study, the
characteristic oligomer size distributions were obtained, which were in agreement with
experimental findings. Aβ42 had a high propensity to form pentameric and hexameric
structures that could self-associate into higher-order oligomers. Structural analysis revealed
that the C-terminal region played a dominant role in Aβ42 oligomer formation, whereas
Aβ40 oligomerization was primarily driven by intermolecular interactions among the central
hydrophobic regions. The N-terminal region (2)AEF played a prominent role in Aβ40
oligomerization but did not contribute to the oligomerization of Aβ42 or the mutants.
Studies conducted in vitro and in vivo suggest that administration of flavonoids, com-
pounds naturally present in many foods including wine and tea, can prevent and reverse Aβ
aggregation, but the mechanism of their action is unknown. Lemkul and Bevan [57]
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employing atomistic, explicit solvent MD simulations investigated the mechanism of Aβ
fibril destabilization by morin which is one of the most effective anti-aggregation flavonoids.
They used a model of mature Aβ and through the course of 24 simulations found that morin
could bind to the ends of the fibrils to block the attachment of an incoming monomeric
peptide and can penetrate into the hydrophobic core to disrupt the D23-K28 salt bridges. It
also modified the backbone hydrogen bonding.
The stability of Aβ42 fibrils and thermodynamics of peptide dissociation were investi-
gated in [58] using all-atom molecular dynamics simulations and pulling one monomer from
the pentameric protofibril of Aβ42. Results indicated that the presence of water molecules
around the D23-K28 salt bridge is crucial to protofibril stability. The extent of packing
between hydrophobic residues regulates the level of hydration in the core of the protofibril
and thus rigidifies the D23-K28 salt bridge. Such studies explore the mechanism of
destabilization of amyloid aggregates which may be important because numerous studies
have found that the insoluble fibrillated form of the peptide also contributes to neurotoxicity,
although the principal toxic species in Alzheimer’s disease are believed to be the soluble,
oligomeric aggregates of Aβ. Membrane disruption and increased ion conductance have
been observed in vitro in the presence of Aβ, and it is assumed that the same phenomena
occur in the brain neurons of Alzheimer's disease patients. Simulations of Aβ in a membrane
bilayer revealed how the peptide interacts with the surrounding lipids and to what extent it
affects lipid behavior and contributes to membrane damage. The results showed that Aβ40 is
capable of disordering the nearby lipids, as well as of decreasing the thickness of the
membrane. During simulations the peptide unfolded and finally acquired a disordered,
extended conformation allowing for extensive electrostatic and hydrogen bonding interac-
tions with lipids [59]. The stability and conformational dynamics of trimeric and pentameric
full-length Aβ42 peptides were investigated by Masman et al. [60] for the purpose of
defining structural elements influencing their stability. The N-terminal part not detected in
NMR was treated as a disordered domain. The models of the oligomer were stable during
100-ns simulations while the β-strand acquired a characteristic twist which facilitated a
compact packing of the side chains from the neighboring β-sheets. It seems that the
hydrophobic core comprising the β2 fragment of the oligomer β-sheet is a stabilizing
element in the process of Aβ aggregation. Destabilization of this crucial β-sheet fragment
emerges as a prospective target for anti-amyloid drugs.
Amyloid Can Be Beneficial for Cells and Also Convenient for Engineers
Amyloid fibrils are cross-β-sheet structures that are primarily associated with several
neurodegenerative diseases. However, amyloid is also a fundamental nonpathological pro-
tein structure (or conformation) utilized by organisms from bacteria to humans. The cross-β-
sheet motif is composed of intermolecular β-sheets arranged along the fibril axis with the β
strands aligned perpendicularly to the fibril axis. Amyloid fibril formation also provides
biologically important entities termed functional amyloids [61] that are present in silkworms
[62, 63] and in mammalian skin [64]. It is also known that pituitary hormones are function-
ing in an amyloid state. Riek and coworkers [65] found that peptide and protein hormones in
secretory granules of the endocrine system are stored in an amyloid-like conformation
composed of cross-β-sheets. Thus, functional amyloids in the pituitary and other organs
can contribute to normal cell and tissue physiology. The hormone amyloids are stored inside
the granules, an “inert” membrane container, and the amyloid fibrils dissociate only upon
secretion. Additionally, the amyloid aggregation of these hormones must be highly
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regulated. This regulation may include the processing of prohormones that aggregate more
slowly than their hormone counterparts [66] or require the presence of helper molecules to
induce aggregation; the latter was demonstrated for prolactin, which lacks a prohormone
stage.
Amyloid, a fibrillar quaternary structure, was first discovered in the context of human
disease and tissue damage. Therefore it was long thought to be detrimental to the host.
However, recent studies have identified functional amyloid fibers in bacteria, fungi, insects,
invertebrates, and humans. Nevertheless, physiological amyloidogenesis requires tight reg-
ulation to avoid toxicity of the produced amyloids. Diverse physiological applications of
amyloids can change our views on the potential treatment of amyloid diseases [61]. The
discovery of native amyloids in mammals provides a key insight into the molecular basis of
both the physiological and pathological role of amyloids.
The examples of useful amyloids include fungal prions, which are involved in prion
replication, the amyloid protein Pmel17 which is involved in biosynthesis of the pigment
melanin in mammals, and the factor XII protein of the hemostatic system which is activated
by amyloid. The Pmel17 protein forms amyloid fibrils that act as a template and accelerate
the covalent polymerization of small reactive molecules into melanin—a critically important
biopolymer that protects against a broad range of cytotoxic insults including UV and
oxidative damage. The Pmel17 amyloid also appears to play a role in diminishing the
toxicity associated with melanin formation by sequestering and minimizing diffusion of
highly reactive melanin precursors [64]. The silkmoth chorion protein is also a natural
protective amyloid. This is the major component of the eggshell, a structure with extraor-
dinary physiological and mechanical properties. Other natural, protective amyloids are fish
chorion, the hydrophobins, and the antifreeze protein from winter flounder.
The phenomenon of the self-assembly of molecules is more and more frequently
exploited to invent new supramolecular structures and materials inspired by biological
systems such as novel biocompatible polymeric structures with excellent physicochemical
properties for new biomedical and industrial applications [62]. A variety of protein and
peptide molecules with various amino acid sequences form highly stable and well-organized
amyloid assemblies under diverse conditions. They display phase states ranging from liquid
crystals to rigid nanotubes. The potential applications of these supramolecular assemblies
can be broader than those of synthetic polymers since one can easily introduce biological
function in addition to their mechanical properties [67]. Self-assembly is a powerful
mechanism for organizing molecular binding blocks into complex structures and aromatic
groups can facilitate this process [68, 69]. For example, the Phe-Phe dipeptide motif from
Alzheimer’s disease β-amyloid protein was able to self-assemble into peptide-based nano-
tubes [70]. The Phe-Phe peptide is of special interest due to its ability to form ordered nano-
assemblies of unique physical, chemical, and mechanical properties [70, 71]. It was shown
that the thermal stability of diphenylalanine peptide nanotubes is significantly higher than
that of a nonassembling dipeptide, dialanine. In addition to thermal stability, the peptide
nanotubes were chemically stable in many organic solvents. Other aromatic dipeptides can
also self-assemble into ordered structures such as tubes, spheres, plates, and hydrogels [71–
75]. Moreover, Phe-Phe nanotube-based electrochemical biosensors have shown a large
increase in their sensitivity upon the modification of the electrode surfaces with the forest-
like nanotube arrays [76–78]. Such bio-inspired materials can be composed of chemically
synthesized biomolecules. In the recent work [79], diphenylalanine nanotubes have been
used to modify carbon electrodes, by physical vapor deposition of peptide nanotubes, of the
electrochemical energy storage devices called supercapacitors. The structural motif of Phe-
Phe forms discrete and stiff nanotubes that can be used for production of discrete nanowires
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with a long persistence length. The same dipeptide building block, made of D-phenylalanine,
resulted in the production of enzymatically stable nanotubes [70]. It was shown that a non-
charged peptide analogue, Ac-Phe-Phe-NH2, self-assembled into similar tubular structures
as did diphenylalanine. A similar peptide, diphenylglycine, self-assembled into ordered
nanospherical assemblies. Other homo-aromatic dipeptides, in which phenyl side chains
were modified with halogen atoms, additional phenyl groups or by alteration of the phenyl
groups and naphthyl groups, or by nitro substitutions, were also investigated. In all cases, the
well-ordered nanostructures were formed in the shape of tubular, spherical, and two-
dimensional structures [71]. Peptide-based nanostructures represent nano-objects of
particular interest, as they are biocompatible, can be easily synthesized in large
amounts, decorated with functional elements, and used in various biological and non-
biological applications.
The significant thermal and chemical stability of the peptide nanotubes could be poten-
tially useful in microelectronics and microelectromechanics as well as for fabrication of
functional nanotechnological devices [80]. Amyloids have unusual properties, for instance,
rigidities varying over four orders of magnitude depending on the nature of intermolecular
forces. The major contribution to their rigidity stems from a generic interbackbone hydrogen
bonding network that can be modulated by the variability of side chain interactions [81].
Especially the aromatic residue, side chain interactions play a role in Phe-Phe and related
peptide nanotubes and in biological processes such as collagen self-assembly which involves
the hydrophobic interactions of Tyr and Phe residues within the C-terminal chain [82, 83].
Usage of bionanostructures in industrial applications requires precise control over self-
assembly of monomeric units and the ability to scale up production of these materials.
A significant challenge is to control the formation of large, homogeneous arrays of
bionanostructures on macroscopic surfaces. The example is the self-assembly of large
arrays of aromatic peptide nanotubes using vapor deposition methods. This approach
allows controlling of the length and density of the nanotubes by supplying the
building blocks from the gas phase. The nanotube arrays can be used to develop
high-surface-area electrodes for energy storage applications, microfluidic chips, and
also highly hydrophobic self-cleaning surfaces [84]. Other interesting applications are
supramolecular gels in nonpolar solvents which are composed of self-assembled nano-
wires. Such studies highlight the role of self-assembly and gelation in the electronic
properties of semiconducting molecular gelators and opens the window for a new
class of conducting materials which may find a wide application in organic electronic
devices [69]. There was also a proposition of using amyloid fibrils as new nanoscale
biomaterials to investigate cell adhesion, migration, and differentiation in vitro. Gras
et al. [85] used peptides with an additional segment motif of the biological cell
adhesion sequence (RGD) or a control sequence (RAD) at the C-terminus of an 11-
residue peptide taken from the amyloidogenic protein transthyretin. The fibrils con-
taining such sequences are bioactive and interact specifically with cells via the
incorporated sequences exposed on the fibril surface. Such functionalized fibrils can
be systematically altered, so it could be possible to generate nanomaterials based on
amyloids to promote interactions for a range of cell types.
One of the most recent and striking examples of the usefulness of a potentially dangerous,
fibril-forming protein was described in [86, 87]. The protein is α-synuclein which partic-
ipates in the Lewy body formation in Parkinson’s disease. The authors fabricated a pea pod-
type gold nanoparticle (AuNP) arrangement into one-dimensional chain structures within the
dielectric amyloid fibrils of α-synuclein. The assembly units composed of α-synuclein
encapsulating AuNPs were manipulated by either hexane or the pH value to induce structural
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rearrangement within the protein coat. The method of encapsulation of noble metal nanoparticles
within dielectric matrices is used to develop fast optoelectric response systems near the surface
plasmon resonance frequency. Light energy can be transported through nanoparticles whose sizes
are substantially smaller than the wavelength of the corresponding light. These AuNP-embedded
amyloid protein nanofibrils exhibited photoconductivitywith visible light—such property is crucial
for the development of a subwavelength size light-guiding nano-optics systems.
Conclusions
The genome-wide analysis revealed that self-complementary amyloidogenic segments are found in
almost all proteins [6]; however, not all proteins form amyloids. There are 40–50 amyloid-
associated diseases identified so far, but only a few proteins were identified to be causative in such
diseases. Such an observation may result from the fact that only the most vulnerable proteins
convert into amyloids. There are protective mechanisms that shield other proteins from this
dangerous behavior. About 500–600 genes/proteins protect young organisms from such diseases,
but their role is diminishing with age, so the ultimate goal would be to find a way to restore their
protective function. Amyloids can be devastating but also beneficial when kept under control by
specific cellular systems. Finally, the unusual properties of amyloid—mechanical, electronic, and
other—can be exploited in many industrial applications. These biological nanostructures do not
cease to inspire new ideas on how to protect the organism against their detrimental effects but also
on how to use them in practical devices.
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